Idenix Pharmaceuticals Announces Completion Of Proof-of-Concept Study For IDX899 In Treatment-Naive HIV-Infected Patients

�Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged
in the